Treatment of multiple sclerosis (MS) has undergone development unprecedented in neurology. With 14 therapeutic options now available to neurologists and their patients, making an accurate choice of the most suitable agent that will protect a patient's CNS from inflammatory damage is of paramount importance. In the absence of head-to-head randomized trials of most of the available therapies, studies using large longitudinal data collections from registries provide us with invaluable information about the relative effectiveness of immunotherapies in different contexts.
from Neurology recent issues http://bit.ly/2Iny7QY
Comments
Post a Comment